Regulatory Challenges in Medical Genetic Testing: Medicare Spending Analysis
A January 2026 report from the Office of Inspector General (OIG) for the U.S. Department of Health and Human Services reveals a 5% increase in Medicare Part B spending on clinical diagnostic laboratory tests, reaching $8.4 billion in 2024. Despite fewer beneficiaries undergoing these tests, spending continues to rise, primarily due to genetic testing, which accounts for 43% of total laboratory spending yet only 5% of the tests covered. These findings highlight potential future regulatory compliance attentions regarding the high costs of genetic testing.
The 2014 Protecting Access to Medicare Act (PAMA) reformed how Medicare calculates payment rates for laboratory tests and requires an annual analysis by the OIG on the top 25 lab tests by expenditure. The 2024 report leveraged Medicare Part B claims under the Clinical Laboratory Fee Schedule to analyze spending trends and identify the most costly tests. This report fulfills statutory obligations and helps policymakers and regulatory bodies pinpoint tests that may warrant further scrutiny.
Regulatory Challenges in Genetic Testing
The increasing focus on high-cost genetic testing presents various compliance challenges. The OIG's findings coincide with heightened federal scrutiny of laboratory and genetic testing fraud, highlighted by the 2025 National Health Care Fraud Takedown by the U.S. Department of Justice (DOJ), involving charges against 49 individuals for $1.17 billion in alleged Medicare fraud related to genetic testing and telehealth.
In recent years, the DOJ has reached several settlements with manufacturers concerning their genetic testing programs and collaborations with laboratories. These areas are poised to remain under regulatory scrutiny, driven by the escalating expenditures in this sector.
Laboratory service providers should carefully evaluate the implications of federal regulations such as the Anti-Kickback Statute and the False Claims Act, as well as the Eliminating Kickbacks in Recovery Act. These regulations may apply to private payer arrangements and could lead to liabilities even when federal healthcare programs are not directly involved.
The OIG report identifies factors that could lead to further regulatory oversight, including billing practices for costly panels, laboratory reporting standards, and interactions between healthcare providers and testing labs. As genetic testing absorbs an increasing share of Medicare laboratory spending, OIG reports are expected to underpin future audits, investigative efforts, and enforcement strategies.